Total operating costs for the quarter were 718K (141K for staff, 404K for R&D and 199K for other working capital). Cash on hand is 2,145K (incorporating proceeds from the Feb/Mar SPP).
Assuming that the 404K R&D expenditure for current PhII HCV trails will terminate this quarter and all things being equal this leaves a further 6 months worth of cash available to pursue Ph1b/2a HIV trial, although I would imagine that R&D costs for these earlier HIV trial would cost less.
Having said that, an out-licensing agreement for BIT225 HCV will significantly reduce the need to tap the mkt for more cash
bluebush
BIT Price at posting:
9.5¢ Sentiment: LT Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)